Titre :

Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis

Auteur(s) :

Levillain, Florence [Auteur]
Institut de pharmacologie et de biologie structurale [IPBS]
Kim, Hongmin [Auteur]
Yonsei University
Woong Kwon, Kee [Auteur]
Yonsei University
Clark, Simon [Auteur]
Public Health England [Salisbury] [PHE]
Cia, Felipe [Auteur]
London School of Hygiene and Tropical Medicine [LSHTM]
Malaga, Wladimir [Auteur]
Yonsei University
Lanni, Faye [Auteur]
Public Health England [Salisbury] [PHE]
Brodin, Priscille [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Gicquel, Brigitte [Auteur]
Génétique mycobactérienne - Mycobacterial genetics
Shenzhen Univerisity [Shenzhen]
Guilhot, Christophe [Auteur]
Yonsei University
Bancroft, Gregory [Auteur]
London School of Hygiene and Tropical Medicine [LSHTM]
Williams, Ann [Auteur]
Public Health England [Salisbury] [PHE]
Jae Shin, Sung [Auteur]
Yonsei University
Poquet, Yannick [Auteur]
Institut de pharmacologie et de biologie structurale [IPBS]
Neyrolles, Olivier [Auteur correspondant]
Institut de pharmacologie et de biologie structurale [IPBS]

Titre de la revue :

Vaccine

Pagination :

1416-1423

Éditeur :

Elsevier

Date de publication :

2020-02

ISSN :

0264-410X

Mot(s)-clé(s) en anglais :

Tuberculosis
Mycobacterium tuberculosis
BCG
Vaccine

Discipline(s) HAL :

Sciences du Vivant [q-bio]/Immunologie/Vaccinologie

Résumé en anglais : [en]

Tuberculosis still claims more lives than any other pathogen, and a vaccine better than BCG is urgently needed. One of the challenges for novel TB vaccines is to protect against all Mycobacterium tuberculosis lineages, ...
Lire la suite >Tuberculosis still claims more lives than any other pathogen, and a vaccine better than BCG is urgently needed. One of the challenges for novel TB vaccines is to protect against all Mycobacterium tuberculosis lineages, including the most virulent ones, such as the Beijing lineage. Here we developed a live attenuated M. tuberculosis mutant derived from GC1237, a Beijing strain responsible for tuberculosis outbreaks in the Canary Islands. The mutant strain is inactivated both in the Rv1503c gene, responsible for surface glycolipid synthesis, and in the two-component global regulator PhoPR. This double mutant is as safe as BCG in immunodeficient SCID mice. In immune-competent mice and guinea pigs, the mutant is as protective as BCG against M. tuberculosis strains of common lineage 4 (Euro-American). By contrast, in mice the vaccine is protective against a M. tuberculosis strain of lineage 2 (East-Asian, Beijing), while BCG is not. These results highlight differences in protection efficacy of live attenuated M. tuberculosis-derived vaccine candidates depending on their genetic background, and provide insights for the development of novel live vaccines against TB, especially in East-Asian countries where M. tuberculosis strains of the Beijing family are highly dominant.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Projet ANR :

Equipements plateforme animalerie infectieuse de haute-sécurité de Midi Pyrénées

Collections :

• Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017

Source :

Harvested from HAL